No changes in lymphocyte muscarinic receptors and platelet monoamine oxidase-B examined as surrogate central nervous system biomarkers in a Faroese children cohort prenatally exposed to methylmercury and polychlorinated biphenyls

Biomarkers

Volumn 14, Issue 2, 2009, Pages 67-76

  Coccini, Teresa ^a   Manzo, Luigi ^a,b   Debes, Frodi ^c   Steuerwald, Ulrike ^c   Weihe, Pl ^c   Grandjean, Philippe ^d,e  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c FAROESE HOSPITAL SYSTEM   (Faroe Islands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Brain development; Cholinergic receptors; MAO B; MeHg; Neurochemical markers; Polychlorinated biphenyls

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; METHYLMERCURY; MUSCARINIC RECEPTOR; POLYCHLORINATED BIPHENYL DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; METHYLMERCURY DERIVATIVE; POLYCHLORINATED BIPHENYL;

ARTICLE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CHILD; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGY; NEUROTOXICITY; OUTCOME ASSESSMENT; PRENATAL EXPOSURE; COHORT ANALYSIS; DRUG EFFECT; ENZYMOLOGY; LYMPHOCYTE; METABOLISM; NEUROPSYCHOLOGICAL TEST; PREGNANCY; THROMBOCYTE;

BIOLOGICAL MARKERS; BLOOD PLATELETS; CHILD; COHORT STUDIES; FEMALE; HUMANS; LYMPHOCYTES; MALE; METHYLMERCURY COMPOUNDS; MONOAMINE OXIDASE; NEUROPSYCHOLOGICAL TESTS; POLYCHLORINATED BIPHENYLS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 66149097062     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902783739     Document Type: Article

References (73)

1. Anthenelli RM, Smith TL, Craig CE, Tabakoff B, Schuckit MA. (1995). Platelet monoamine oxidase activity levels in subgroups of alcoholics: diagnostic, temporal, and clinical correlates. Biol Psychiatry 38:361-368.
2. Arrojo M, Baca-Garcia E, Perez-Rodriguez MM, Dolengevich-Segal H, Navio-Acosta M, Rodriguez-Salgado B, Saiz-Ruiz J. (2007). Platelet monoamine oxidase activity in obsessive-compulsive disorder. Eur Psychiatry 22:525-529.
3. Basu N, Stamler CJ, Loua KM, Chan HM. (2005). An interspecies comparison of mercury inhibition on muscarinic acetylcholine receptor binding in the cerebral cortex and cerebellum. Toxicol Appl Pharmacol 205:71-76.
4. Beyrouty P, Stamler C, Liu JN, Kubow S, Chan HM. (2006). Effects of prenatal methylmercury exposure on brain monoamine oxidase activity and neurobehavior of rats. Neurotoxicol Teratol 28:251-259.
5. Blanco C, Orensanz-Munoz L, Blanco-Jerez C, Saiz-Ruiz J. (1996). Pathological gambling and platelet MAO activity: A psychobiological study. Am J Psychiatry 153:119-121.
6. Carrasco JL, Diaz-Marsa M, Hollander E, Cesar J, Saiz-Ruiz J. (2000). Decreased platelet monoamine oxidase activity in female bulimia nervosa. Eur Neuropsychopharmacol 10:113-117. (Pubitemid 30120040)
7. Castoldi AF, Candura SM, Costa P, Manzo L, Costa LG. (1996). Interaction of mercury compounds with muscarinic receptor subtypes in the rat brain. Neurotoxicology 17:735-742.
8. Castoldi AF, Blandini F, Randine G, Samuele A, Manzo L, Coccini T. (2006). Brain monoaminergic neurotransmission parameters in weanling rats after perinatal exposure to methylmercury and 2,29,4,49,5,59-hexachlorobiphenyl (PCB153). Brain Res 1112:91-98.
9. Castoldi AF, Johansson C, Onishchenko N, Coccini T, Roda E, Vahter M, Ceccatelli S, Manzo L. (2008a). Human developmental neurotoxicity of methylmercury: Impact of variables and risk modifiers. Regul Toxicol Pharmacol 51:201-214.
10. Castoldi AF, Onishchenko N, Johansson C, Coccini T, Roda E, Vahter M, Ceccatelli S, Manzo L. (2008b). Neurodevelopmental toxicity of methylmercury: Laboratory animal data and their contribution to human risk assessment. Regul Toxicol Pharmacol 51:215-229.
11. Chakrabarti SK, Loua KM, Bai C, Durham H, Panisset J-C. (1998). Modulation of monoamine oxidase activity in different brain regions and platelets following exposure of rats to methylmercury. Neurotoxicol Teratol 20:161-168.
12. Checkoway H, Echeverria D, Moon J-D, Heyer N, Costa LG. (1994). Platelet monoamine oxidase B activity in workers exposed to styrene. Int Arch Occup Environ Health 66:359-362.
13. Chen K, Wu HF, Shih JC. (1993). The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem 61:187-190.
14. Coccini T, Castoldi AF, Gandini C, Randine G, Vittadini G, Baiardi P, Manzo L. (2002). Platelet monoamine oxidase B activity as a state marker for alcoholism: Trend over time during withdrawal and influence of smoking and gender. Alcohol Alcohol 37:566-572.
15. Coccini T, Randine G, Castoldi AF, Acerbi D, Manzo L. (2007a). Methylmercury interaction with lymphocyte cholinergic muscarinic receptors in developing rats. Environ Res 103:229-237.
16. Coccini T, Roda E, Castoldi AF, Goldoni M, Poli D, Bernocchi G, Manzo L. (2007b). Perinatal co-exposure to methylmercury and PCB153 or PCB126 in rats alters the cerebral cholinergic muscarinic receptors at weaning and puberty. Toxicology 238:34-48.
17. Coccini T, Randine G, Candura SM, Nappi R, Prockop LD, Manzo L. (2000). Low-level exposure to methylmercury modifies muscarinic cholinergic receptor binding characteristics in rat brain and lymphocytes: physiologic implications and new opportunities in biological monitoring. Environ Health Perspect 108:29-33.
18. Coccini T, Randine G, Castoldi AF, Balloni L, Baiardi P, Manzo L. (2005). Lymphocyte muscarinic receptors and platelet monoamine oxidase- B as biomarkers of CNS function. Effects of age and gender in healthy humans. Environ Toxicol Pharmacol 19:715-720.
19. Coccini T, Randine G, Castoldi AF, Grandjean P, Ostendorp G, Heinzow B, Manzo L. (2006). Effects of developmental co-exposure to methylmercury and 2,29,4,49,5,59-hexachlorobiphenyl (PCB153) on cholinergic muscarinic receptors in rat brain. Neurotoxicology 27:468-477.
20. Costa LG, Kaylor G, Murphy SD. (1990). In vitro and in vivo modulation of cholinergic muscarinic receptors in rat lymphocytes and brain by cholinergic agents. Int J Immunopharmacol 12:67-75.
21. Danielczyk W, Streifler M, Konrad C, Riederer P, Moll G. (1988). Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand 78:730-736.
22. Dick DM, Aliev F, Kramer J, Wang JC, Anthony Hinrichs A, Bertelsen S, Kuperman S, Schuckit M, Nurnberger Jr J. Edenberg HJ, Porjesz B, Begleiter H, Hesselbrock V, Goate A, Bierut L. (2007). Association of CHRM2 with IQ: Converging evidence for a gene influencing intelligence. Behav Genet 37:265-272.
23. Donnelly CH, Murphy DL. (1977). Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26:853-858.
24. Eriksson P, Lundkvist U, Fredriksson A. (1991). Neonatal exposure to 3,3',4,4'-tetrachlorobiphenyl: Changes in spontaneous behaviour and cholinergic muscarinic receptors in the adult mouse. Toxicology 69:27-34.
25. Eriksson M, Berggren U, Fahlke C, Engel J, Balldin J. (2006). Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men. J Neural Transm 113:33-41.
26. Fitzgerald BB, Costa LG. (1993). Modulation of muscarinic receptors and acetylcholinesterase activity in lymphocytes and in brain areas following repeated organophosphates exposure in rats. Fundam Appl Toxicol 20:210-216.
27. Fowler CJ, Tipton KF, MacKay AVP, Youdim MBH. (1982). Human platelet monoamine oxidase: A useful enzyme in the study of psychiatric disorders? Neuroscience 7:1577-1594.
28. Gelowitz DL, Richardson JS, Wishart TB, Yu PH, Lai CT. (1994). Chronic L-deprenyl or L-amphetamine: Equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 47:41-45.
29. Gosso MF, van Belzen M, de Geus EJ, Polderman JC, Heutink P, Boomsma DI, Posthuma D. (2006). Association between the CHRM2 gene and intelligence in a sample of 304 Dutch families. Genes Brain Behav 5: 577-584.
30. Grandjean P, Weihe P, Burse VW, Needham LL, Storr-Hansen E, Heinzow B, Debes F, Murata K, Simonsen H, Ellefsen P, Budtz-Jørgensen E, Keiding N, White RF. (2001). Neurobehavioral deficits associated with PCB in 7-year-old children prenatally exposed to seafood neurotoxicants. Neurotoxicol Teratol 23:305-317.
31. Grandjean P, Weihe P, White RF, Debes F, Araki S, Yokoyama K, Murata K, Sørensen N, Dahl R, Jørgensen PJ. (1997). Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol 19:417-428.
32. Grandjean P, Budtz-Jørgensen E, White RF, Jørgensen PJ, Weihe P, Debes F. Keiding. (1999). Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years. Am J Epidemiol 150:301-305.
33. Grandjean P, Budtz-Jørgensen E, Jørgensen PJ, Weihe P. (2005). Umbilical cord mercury concentration as biomarker of prenatal exposure to methylmercury. Environ Health Perspect 113:905-908.
34. Grandjean P, Landrigan PJ. (2006). Developmental neurotoxicity of industrial chemicals. Lancet 368:2167-2178.
35. Griffin SL, van Reekum R, Masanic C. (2003). A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. J Neuropsychiatr Clin Neurosci 15:17-26.
36. Holschneider DP, Chen K, Seif I, Shih JC. (2001). Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res Bull 56:453-462.
37. IPCS. (1993). Polychlorinated Biphenyls and Terphenyls, 2nd edn. Environmental Health Criteria 140. Geneva: World Health Organization.
38. Jacobson JL, Jacobson SW. (1997). Teratogen update: polychlorinated biphenyls. Teratology 55:338-347.
39. Johansson C, Castoldi AF, Onishchenko N, Manzo L, Vahter M, Ceccatelli S. (2007). Neurobehavioural and molecular changes induced by methylmercury exposure during development. Neurotox Res 11:241-260.
40. Kaneda Y, Fujii A, Nagamine I. (2001). Platelet serotonin concentrations in medicated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 25:983-992.
41. Leblond L, Beaufort C, Delerue F, Durkin TP, (2002). Differential roles for nicotinic and muscarinic cholinergic receptors in sustained visuo-spatial attention? A study using a 5-arm maze protocol in mice. Behav Brain Res 128:91-102.
42. Limke TL, Heidemann SR, Atchison WD. (2004). Disruption of intraneuronal divalent cation regulation by methylmercury: Are specific targets involved in altered neuronal development and cytotoxicity in methylmercury poisoning? Neurotoxicology 25:741-760.
43. Manzo L, Artigas F, Martinez E, Mutti A, Bergamaschi E, Nicotera P, Tonini M, Candura SM, Ray, DE, Costa LG. (1996). Biochemical markers of neurotoxicity. A review of mechanistic studies and applications. Hum Exp Toxicol 15:S20-S35.
44. Manzo L, Castoldi AF, Coccini T, Prockop LD. (2001). Assessing effects of neurotoxic pollutants by biochemical markers. Environ Res A 85:31-36.
45. Masuyama K, Uno K, Minoda R, Eura M, Samejima Y, Ishikawa T. (1996). Muscarinic acetylcholine receptors in patients with Meniere's disease. Acta Oto-Laryngol (Stockholm) 116:369-373.
46. Meltzer HY, Zureick JL. (1987). Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: sex and race interactions. Psychiatry Res 22:99-109.
47. Muck-Seler D, Sagud M, Mustapic M, Nedic G, Babic A, Mihaljevic Peles A, Jakovljevic M, Pivac N. (2008). The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression. Prog Neuro-Psychopharmacol Biol Psychiatry 32:1195-1198.
48. Murphy DL, Wyatt RJ. (1972). Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 238:225-226.
49. NRC, National Research Council. (2000). Toxicological effects of methylmercury. Washington DC: National Academy Press.
50. Oreland L, Fowler C. (1982). Brain and platelet monoamine oxidase activities in relation to central monoaminergic activity in mice and man. In: Kamijo K, Usdin E, Nagatsu T, editors. Monoamine Oxidase: Basic and Clinical Frontiers. Amsterdam: Excerpta Medica. p. 312-320.
51. Oreland L, Nilsson K, Damberg M, Hallman J. (2007). Monoamine oxidases - activities, genotypes and the shaping of behaviour. J Neural Transm 114:817-822.
52. Perry RJ, Hodges JR. (1999). Attention and executive deficits in Alzheimer's disease: A critical review. Brain 122:383-404.
53. Pivac N, Knezevic J, Kozaric-Kovacic D, Dezelijin M, Mustapic M, Rak D, Mitijevic T, Pavelic J, Muck-Seler D. (2007). Monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity in combat-related posttraumatic stress disorders. J Affect Disord 103:131-138.
54. Prado VF, Martins-Silva C, de Castro BM, Lima RF, Barros DM, Amaral E, Ramsey AJ, Sotnikova TD, Ramirez MR, Kim HG, Rossato JI, Koenen J, Quan H, Cota VR, Moraes MF, Gomez MV, Guatimosim C, Wetsel WC, Kushmerick C, Pereira GS, Gainetdinov RR, Izquierdo I, Caron MG, Prado MA. (2006). Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 51:601-612.
55. Rabey JM, Grynberg E, Graff E. (1991). Changes of muscarinic cholinergic binding by lymphocyte in Parkinson's disease with and without dementia. Ann Neurol 30:847-850.
56. Rabey JM, Lewis A, Graff E, Korczyn AD. (1992). Decreased (3H) quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette syndrome. Biol Psychiatry 31:889-895.
57. Rice DC, Barone S Jr, (2000). Critical periods of vulnerability for the developing nervous system: Evidence from human and animal models. Environ Health Perspect 108:511-531.
58. Riederer P, Danielczyk W, Grünblatt E. (2004). Monoamine oxidase- B inhibition in Alzheimer's disease. NeuroToxicology 25:271-277. (Pubitemid 38044188)
59. Rodier PM. (1994). Vulnerable periods and processes during central nervous system development. Environ Health Perspect 102:121-124.
60. Sandler M, Reveley MA, Glover V. (1981). Human platelet monoamine oxidase activity in health and disease: A review. J Clin Pathol 34:292-302. (Pubitemid 11153594)
61. Snell LD, Glanz J, Tabakoff B. (2002). Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: Activity, affinity labelling, and protein measurements. Alcohol Clin Exp Res 26:1105-1113.
62. Stamler CJ, Abdelouahab N, Vanier C, Mergler D, Chan HM. (2006). Relationship between platelet monoamine oxidase-B (MAO-B) activity and mercury exposure in fish consumers from the Lake St. Pierre region of Que., Canada. Neurotoxicology 27:429-436.
63. Steuerwald U, Weihe P, Jørgensen PJ, Bjerve K, Brock J, Heinzow B, Budtz-Jørgensen E, Grandjean P. (2000). Maternal seafood diet, methylmercury exposure, and neonatal neurologic function. J Pediatr 136:599-605.
64. Stewart PW, Reihman J, Lonky EI, Darvill TJ. (2003). Cognitive development in preschool children prenatally exposed to PCBs and MeHg. Neurotoxicol Teratol 25:11-22.
65. Sullivan JL, Baenziger JC, Wagner DL, Rauscher FP, Nurnberger JI Jr, Holmes JS. (1990). Platelet MAO in subtypes of alcoholism. Biol Psychiatry 27:911-922.
66. Tayebati SK, Codini M, Gallai V, Mannino F, Parnetti L, Ricci A, Sarchielli P, Amenta F. (1999). Radioligand binding assay of M1-M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 99:224-229. (Pubitemid 29518235)
67. Tayebati SK, Amenta F, Amici S, El-Assouad D, Gallai V, Ricci A, Parnetti L. (2001). Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: A marker of cholinergic dysfunction? J Neuroimmunol 121:126-131.
68. Verkes RJ, Van der Mast RC, Kerkhof AJ, Fekkes D, Hengeveld MW, Tuyl JP, Van Kempen GM. (1998). Platelet serotonin, monoamine oxidase activity, and 3H paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biol Psychiatry 15:740-746.
69. Vincent DR, Bradshaw WS, Booth GM, Seegmiller RE, Allen SD. (1992). Effect of PCB and DES on rat monoamine oxidase, acetylcholinesterase, testosterone and estradiol ontogeny. Bull Environ Contam Toxicol 48:884-893.
70. Wess J, Eglen RM, Gautam D. (2007). Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development. Nature Rev Drug Discov 6:721-733.
71. Whitfield JB, Pang D, Bucholz KK, Madden PA, Heath AC, Statham DJ, Martin NG. (2000). Monoamine oxidase: Associations with alcohol dependence, smoking and other measures of psycopathology. Psychol Med 30:443-454.
72. Wyatt RT, Murphy DL, Belmaker R, Cohen S, Donnelly CH, Pollin W. (1973). Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. Science 179:916-918.
73. Yuan Y, Atchison WD. (1993). Disruption by methylmercury of membrane excitability and synaptic transmission of CA1 neurons in hippocampal slices of the rat. Toxicol Appl Pharmacol 120:203-215.